Dipeptidyl peptidase-4 inhibitors may be associated with an increased incidence of malignancy
1. Sitagliptin demonstrated the most prominent malignancy-related safety signal among the dipeptidyl peptidase-4 inhibitors studied. Evidence Rating Level: 2 (Good) ...


![ABCD2 Score: Predicting Early Stroke Risk After Transient Ischemic Attack (TIA) [Classics Series]](https://www.2minutemedicine.com/wp-content/uploads/2013/05/web-cover-classics-with-logo-medicine-BW-small-jpg-350x250.jpg)


